However, the percentage of tumors with cytokeratin-5/6 positivity in the basement membrane (BM; a surrogate for tumor invasion) was reduced by treatment with either JBS2, lapatinib, or JBS2 + lapatinib (Figure 4F). This evidence concerns the gene KRT5 and neoplasm.